I. Khalili et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAChitosan as an adjuvant for preparation of inactivated influenza vaccineI. Khalili 1 , M. Fathi Najafi 1 and S. Avagyan 21Razi Vaccine & Serum Research Inst.Northwest, Iran2Agrarian National University Armenia ANUA Yerevan, ArmeniaInfluenza A viruses infects a wide range of animal species and human. Among the avian influenza virus (AIV) subtypes,H9N2 would be used for rapid intervention should be safe to use and highly effective after a single administration. Chitosanmicroparticles have already been proposed as a new adjuvant in inactivated avian Influenza (H9N2) vaccine immunization. Virushas the potential to cause an influenza pandemy and vaccination is a common solution for this problem. The aim of the presentwork was to investigate the potential utility of chitosan microparticles as new parenterally vaccine delivery vehicles.For this purpose, chitosan microparticles were prepared according to a modified ionic gelation method and inactivatedantigen was loaded in 1 HAU concentration. Loading capacity of microparticles was determined by Hemaglutinization (HA)method. ISA70 vaccine as a standard adjuvant with same loading size was used in beside. For vaccine-antibody response assay,different volumes of prepared vaccines (0.2, 0.4 and 0.6 ml) were injected via subcutaneous rout in 21-days-old specific pathogenfree cheekiness. Vaccine induced AIV-specific antibodies after single vaccination, measured at 6 weeks after vaccination withHemagglutinin Inhibition (HI) and ELISA methods.Elisa and HI Log 2 total mean titer of chitosan groups were significantly increased in 3 weeks after vaccine administration(p0.05). Titer of ISA70experimental vaccine in mentioned preparations condition was not reasonable.So, these kinds of vaccines induce appropriate antibody titers after a single immunization and with a low dose of antigen.Also, chitosan microparticles represent an interesting new platform for antigen delivery and a promising adjuvant candidate forH9N2 inactivated influenza vaccine.Keywords: Chitosan, microparticle, adjuvant, influenza, virus, ELISABiographyIraj Khalili is Director Manager at Razi vaccine and serum research institute. He graduated at DVM in 1995. He started his job at Razi Companyin 1997 in fi eld of pharmaceutical and vaccine producing. There are more than 60 biological productions in fi eld of veterinary and medicine. He isincharge of Razi vaccine and serum research institute (Northwest) branch since 2007. He is planning his Ph.D. pre-defence at ANUA in Armenia.iraj_dv4953@yahoo.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 120
Hemanta Koley et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAImmunogenicity and protective efficacy of multi-serotype outer membrane vesicles ofshigellae in animal modelHemanta Koley and Soma MitraNational Institute of Cholera and Enteric Diseases, IndiaImmunization of adult female mice with outer membrane vesicles (OMVs) of Shigella boydii type 4 protected their offspringpassively from shigellosis. Now, we have advanced our research by formulating multi-serotype outer membrane vesicles(MOMVs) mixing the OMVs of S. dysenteriae 1 Δstx, S. flexneri 2a, S. flexneri 3a, S. flexneri 6, S. boydii type 4 and S. sonnei toachieve a broad spectrum protection against shigellosis. Adult mice were immunized orally with 50μg of MOMVs, four timesat weekly intervals. Immunological parameters were observed at various time points, before, during and after immunization,in adult mice. Passive protection was examined in their offspring by measuring protective efficacy and studying intestinalcolonization, after challenging with various Shigella strains. Immunized dams exhibited a consistent broad spectrum antibodyresponse. Three to four day-old offspring of immunized dams showed significant long term passive protection against Shigellaflexneri 2a, 3a, 6, S. boydii type 2 and S. dysenteriae 1 challenge. Their stomach extracts, containing mainly milk from the dams,have also exhibited significant levels of anti-MOMVs immunoglobulins. In conclusion, MOMVs formulation represents an easy,safe immunization strategy that was found suitable to provide complete passive protection to the neonatal mice against all fourserogroups of Shigellae. This formulation could be exploited for the development of a novel non-living vaccine against humanshigellosis in our near future.BiographyHemanta Koley, after completion of his master’s degree in Human Physiology from Calcutta University, he joined in NICED, Beliaghata, Calcutta,India, for his Ph.D. work. In 1996, he worked as Associate Professor in College of Medical Sciences, Nepal, where he devoted entire heartily inteaching medical students till 2001. He moved to Rutgers-The State University of New Jersey, New Brunswick, USA for postdoctoral research. Healso worked in Gastroenterology Section, Harvard Medical School as Research Associate. His present research interest is to understand signaltransduction pathways in immune and infl ammatory cells during diarrhoea and also to study the nature of protection against diarrhoeal pathogenslike Vibrio cholera, Salmonella and Shigella in different animal models. He has published 43 original papers and 50 abstracts in his credit. He hassecured patent for a process for the preparation of Cholera Vaccine-VA1.3. (European Patent Offi ce; Patent No. - 97309957.5-2105 on 19/05/98).Dr. Koley received Young Scientist Award in IUPS, August 26-31, 2001.hemantakoley@hotmail.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 121
- Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
- Page 3 and 4:
Medical SciencesISSNAddiction Resea
- Page 5 and 6:
Impact Factors (IF) and Index Coper
- Page 7 and 8:
111 th OMICS Group Conference3 rd I
- Page 9 and 10:
Journal of Clinical & Cellular Immu
- Page 11 and 12:
111 th OMICS Group Conference3 rd I
- Page 13 and 14:
111 th OMICS Group Conference3 rd I
- Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
- Page 17 and 18:
Immunology Summit-2013OMICS Group i
- Page 19 and 20:
Probiotics-2013OMICS Group is organ
- Page 21 and 22:
Virology-2013OMICS Group is organiz
- Page 23 and 24:
111 th OMICS Group Conference3 rd I
- Page 25 and 26:
Because of heightened awareness of
- Page 27 and 28:
111 th OMICS Group Conference3 rd I
- Page 29 and 30:
111 th OMICS Group Conference3 rd I
- Page 31 and 32:
111 th OMICS Group Conference3 rd I
- Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
- Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
- Page 37 and 38:
111 th OMICS Group Conference3 rd I
- Page 39 and 40:
Robert E. Sievers et al., J Vaccine
- Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
- Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
- Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
- Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
- Page 49 and 50:
Track 33: Novel Approaches in Desig
- Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
- Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
- Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
- Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
- Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
- Page 61 and 62:
Track 44: Vaccines against Infectio
- Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
- Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
- Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
- Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
- Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
- Page 73 and 74: Young Research ForumSession ChairPe
- Page 75 and 76: Humberto Hernandez et al., J Vaccin
- Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
- Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
- Page 81 and 82: Kaissar Tabynov et al., J Vaccines
- Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
- Page 85 and 86: Track 5 & 95: Manufacturing, Produc
- Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
- Page 89 and 90: Obradovic Zarema et al., J Vaccines
- Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
- Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
- Page 95 and 96: 111 th OMICS Group Conference3 rd I
- Page 97 and 98: Regina Heidenreich et al., J Vaccin
- Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
- Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
- Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
- Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
- Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
- Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
- Page 111 and 112: Byung Chul Kim et al., J Vaccines V
- Page 113 and 114: STS. Chitradevi et al., J Vaccines
- Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
- Page 117 and 118: 111 th OMICS Group Conference3 rd I
- Page 119: Afshineh Latifynia et al., J Vaccin
- Page 123 and 124: Aleksandar Masic et al., J Vaccines
- Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
- Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
- Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
- Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
- Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
- Page 135 and 136: Mathan Periasamy et al., J Vaccines
- Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
- Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
- Page 141 and 142: 111 th OMICS Group Conference3 rd I
- Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
- Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
- Page 147 and 148: Belachew Etana et al., J Vaccines V
- Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
- Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
- Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
- Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
- Page 157 and 158: Veronica Rainone et al., J Vaccines
- Page 159 and 160: Page 159
- Page 161 and 162: Previous111 th OMICS Group Conferen
- Page 163 and 164: PreviousWorld Congress and Expo onB